ES2196018T3 - Vacunas de adenovirus recombinantes. - Google Patents

Vacunas de adenovirus recombinantes.

Info

Publication number
ES2196018T3
ES2196018T3 ES94305656T ES94305656T ES2196018T3 ES 2196018 T3 ES2196018 T3 ES 2196018T3 ES 94305656 T ES94305656 T ES 94305656T ES 94305656 T ES94305656 T ES 94305656T ES 2196018 T3 ES2196018 T3 ES 2196018T3
Authority
ES
Spain
Prior art keywords
administrative
recombinant adenovirus
immunity
antibodies
hot blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94305656T
Other languages
English (en)
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Murthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2196018T3 publication Critical patent/ES2196018T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)

Abstract

ESTE INVENTO PROPORCIONA UN METODO DE PRODUCIR ANTICUERPOS O CELULAS MEDIADORAS DE INMUNIDAD EN UN ORGANISMO INFECCIOSO EN UN MAMIFERO DE SANGRE CALIENTE QUE COMPRENDE ADMINISTRAR A DICHO MAMIFERO DE SANGRE CALIENTE INTRANASALMENTE, INTRAMUSCULARMENTE O SUBCUTANEAMENTE, ADENOVIRUS RECOMBINANTE VIVO EN EL QUE LA PROTEINA ESTRUCTURAL DEL VIRUS ESTA SIN MODIFICAR DESDE QUE EL ADENUVIRUS RECOMBINANTE SE PRODUCE A PARTIR DEL ADENOVIRUS NATIVO, Y QUE CONTIENE EL GEN CODIFICADO POR EL ANTIGENO CORRESPONDIENTE A DICHOS ANTICUERPOS O INDUCE DICHA INMUNIDAD EN LA CELULA MEDIADORA.
ES94305656T 1993-08-11 1994-07-29 Vacunas de adenovirus recombinantes. Expired - Lifetime ES2196018T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10523293A 1993-08-11 1993-08-11
US27628994A 1994-07-20 1994-07-20

Publications (1)

Publication Number Publication Date
ES2196018T3 true ES2196018T3 (es) 2003-12-16

Family

ID=26802374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94305656T Expired - Lifetime ES2196018T3 (es) 1993-08-11 1994-07-29 Vacunas de adenovirus recombinantes.

Country Status (16)

Country Link
EP (1) EP0638316B1 (es)
JP (1) JPH07145079A (es)
KR (1) KR100347220B1 (es)
AT (1) ATE241385T1 (es)
AU (2) AU6889194A (es)
BR (1) BR9403202A (es)
CA (1) CA2130202A1 (es)
DE (1) DE69432730T2 (es)
DK (1) DK0638316T3 (es)
ES (1) ES2196018T3 (es)
FI (1) FI113621B (es)
HU (1) HUT69793A (es)
IL (1) IL110560A (es)
NZ (1) NZ264190A (es)
PT (1) PT638316E (es)
SG (1) SG43029A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP0935659A1 (en) * 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AU2002347317B2 (en) 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
WO2006091722A2 (en) 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
BRPI0504782A (pt) 2005-11-01 2007-09-18 Fundacao Oswaldo Cruz adenovìrus recombinantes, processo de construção de adenovìrus recombinantes, composição de vacina contra toxoplasmose, e método de imunização contra infecções causadas pelo parasita t. gondii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
ES2115622T5 (es) * 1990-10-17 2003-03-16 Us Health Clones moleculares de hiv-1 y usos de los mismos.
AU9179891A (en) * 1990-12-19 1992-07-22 Epitope, Inc. Hiv reverse transcriptase vaccine
ZA935355B (en) * 1992-08-07 1995-01-23 American Home Prod Recombinant andenovirus vaccines

Also Published As

Publication number Publication date
KR950005326A (ko) 1995-03-20
HU9402309D0 (en) 1994-10-28
DE69432730T2 (de) 2004-03-25
IL110560A (en) 1998-10-30
FI113621B (fi) 2004-05-31
AU4850697A (en) 1998-03-26
PT638316E (pt) 2003-10-31
DK0638316T3 (da) 2003-09-22
JPH07145079A (ja) 1995-06-06
KR100347220B1 (ko) 2003-02-26
FI943626L (fi) 1995-02-12
CA2130202A1 (en) 1995-02-12
HUT69793A (en) 1995-09-28
DE69432730D1 (de) 2003-07-03
EP0638316B1 (en) 2003-05-28
NZ264190A (en) 1997-06-24
HK1009934A1 (en) 1999-06-11
ATE241385T1 (de) 2003-06-15
IL110560A0 (en) 1994-11-11
EP0638316A1 (en) 1995-02-15
SG43029A1 (en) 1997-10-17
BR9403202A (pt) 1995-04-11
FI943626A0 (fi) 1994-08-04
AU6889194A (en) 1995-02-23

Similar Documents

Publication Publication Date Title
ES2196018T3 (es) Vacunas de adenovirus recombinantes.
DE69434475D1 (de) Impfstoff gegen prostatakrebs
PT584348E (pt) Vacina genetica para virus da imunodeficiencia
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
DK1223973T3 (da) Fremgangsmåde til at udtrykke antigener på overfladen af antigenpræsenterede celler ved fotokemisk internalisation
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
DE69834921D1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
DE69408342D1 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
DE3781168D1 (de) Silicon verbindungen mit acrylfunktionen.
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DE59010787D1 (de) Erythropoietin (EPO)-Peptide und dagegen gerichtete Antikörper
DK0800578T3 (da) Rekombinant monoklonalt anti-idiotype antistof 3H1
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
DE3750125D1 (de) Biologische eindämmung.
ATE160222T1 (de) Photoaktivierung von proteinen zu konjugationszwecken
ATE318312T1 (de) Monoklonaler anti-idiotypischer antikörper 11d10 aus der maus und methoden zu dessen verwendung
ES2126145T3 (es) Redireccionamiento de anticuerpos.
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
DK0542923T3 (da) Liposomer, som giver thumusafhængig hjælp til svage vaccineantigener
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE119203T1 (de) Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus.
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
ATE134874T1 (de) Synoviale phospholipasen
FI885169L (fi) Monoklonaalinen vasta-aine, joka tunnistaa N-asetyylineuramiinihapon -järjestyksessä, sen käyttö ja sitä tuottava hybridooma